antibody

MSD to Buy B-Cell Depletion Therapy from Curon

Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.

News

Leaving the Patent Cliff Behind

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

INOSIM GmbH

Predictive Simulation in Pharma Production

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

CHEManager International c/o Wiley-VCH GmbH

Event Sponsorship: Next Generation Batteries and Hydrogen

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.